We are live on
!
Find out more
CC
Caspian Capital Portfolio holdings
AUM
$103M
This Fund
S&P 500
This Quarter
Est. Return
+19.18%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$55.4M
AUM Growth
-$6.16M
(-10%)
Cap. Flow
-$13.4M
Cap. Flow
% of AUM
-24.18%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
2
Reduced
–
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pediatrix Medical
MD
|
+$3.72M |
| 2 |
Bausch + Lomb
BLCO
|
+$2.13M |
| 3 |
HDSN
Hudson Technologies
HDSN
|
+$1.45M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FTAI Aviation
FTAI
|
+$20.7M |
| 2 |
MCAFR
Mountain Crest Acquisition Corp. IV Rights
MCAFR
|
+$15.2K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 67.93% |
| 2 | Healthcare | 18.58% |
| 3 | Materials | 13.47% |
Similar funds
SPCM
1CP
VCM
EFT
RC
OPAM
ES
GWL
Caspian Capital's Q2 2024 Portfolio in Review
As of Q2 2024, Caspian Capital held 7 positions worth $55.4M, down 10% from $61.6M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Caspian Capital withdrew a net $13.4M in Q2 2024, closing 2 positions. Its most notable exit was FTAI Aviation, an estimated $20.7M position sold in full.
By sector, the portfolio is most concentrated in Industrials at 68% of assets, down from 78% a quarter earlier, followed by Healthcare and Materials.
Against the trend, Caspian Capital opened a new position in Pediatrix Medical worth $3.4M.
- Caspian Capital's largest Q2 2024 buy was Pediatrix Medical: 450,000 shares worth $3.4M.
- Caspian Capital added most to Bausch + Lomb in Q2 2024, an estimated $2.13M increase.
- Caspian Capital fully exited FTAI Aviation in Q2 2024, selling an estimated $20.7M.
- Caspian Capital's ten largest holdings make up 100% of its $55.4M portfolio in Q2 2024.
- Caspian Capital opened 1 new position and closed 2 in Q2 2024.
- Caspian Capital's portfolio value fell 10% quarter-over-quarter to $55.4M.
Based on Caspian Capital's 13F filing for Q2 2024, filed 14 Aug 2024.